Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer and rare diseases. Headquartered in Wilmette, Illinois, the company's pipeline features novel radiopharmaceuticals for oncology and a late-stage therapy for Wilson disease. The company's lead rare disease candidate, ALXN1840, is an oral therapy designed to mobilize and sequester copper in patients with Wilson disease. In oncology, Monopar is advancing a suite of radiopharmaceuticals built upon MNPR-101, a first-in-class humanized monoclonal antibody that targets the urokinase plasminogen activator receptor (uPAR) overexpressed in various solid tumors. These oncology programs include MNPR-101-Zr for imaging, as well as MNPR-101-Lu and MNPR-101-Ac for targeted radiotherapy. Operating primarily in the United States, Monopar builds its pipeline through both in-house research and strategic licensing agreements to address areas of significant unmet medical need.
